DiaMedica Therapeutics elects two new directors at 2021 AGM

DiaMedica Therapeutics Inc.

Shareholders elected Amy Burroughs and Charles Semba, M.D. as directors effective immediately.
Burroughs will serve on Audit and Nominating & Governance committees; Semba on Audit and Compensation committees.
Four incumbent directors re-elected: Pilnik, Giuffre, Parsons, Pauls. All received >96% votes for.
Baker Tilly US, LLP appointed as independent auditor for FY2021 with 10,734,645 votes for, none against.
Quorum of 57.2% present; 10,748,667 shares voted out of 18,786,157 outstanding.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles Semba, M.D.

director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2021-07-15
Filed: July 16, 2021, 7:59 PM ET

the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.

Appointed

Amy Burroughs

director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2021-07-15
Filed: July 16, 2021, 7:59 PM ET

the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Semba, M.D. was elected as director at DiaMedica Therapeutics Inc..

Action: elected
Role: director

Exact text from the filing

the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Burroughs was elected as director at DiaMedica Therapeutics Inc..

Action: elected
Role: director

Exact text from the filing

the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-21-017038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.